You are here

  • Home
  • Archive
  • Volume 32, Issue 7
  • Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

Citation Tools

Article menu
Download PDFPDF
Clinical trial
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Macchia G, Jereczek-Fossa BA, Lazzari R, et al
Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic/persistent/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3/RAD)
International Journal of Gynecologic Cancer 2022;32:939-943.